Correction: COVID-19 Vaccine-Induced Myocarditis and Pericarditis: Towards Identification of Risk Factors

IF 3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Global Heart Pub Date : 2024-01-08 DOI:10.5334/gh.1276

Laura C. Zwiers, David S. Y. Ong, D. Grobbee

引用次数: 0

Abstract

This article details a correction to: Zwiers LC, Ong DSY, Grobbee DE. COVID-19 Vaccine-Induced Myocarditis and Pericarditis: Towards Identification of Risk Factors. Global Heart. 2023; 18(1): 39. DOI: https://doi.org/10.5334/gh.1252

查看原文本刊更多论文

更正：COVID-19 疫苗诱发的心肌炎和心包炎：识别风险因素

本文详细介绍了对Zwiers LC, Ong DSY, Grobbee DE.COVID-19 疫苗诱发的心肌炎和心包炎：风险因素的识别》。全球心脏。2023; 18(1):39.DOI: https://doi.org/10.5334/gh.1252

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Global Heart Medicine-Cardiology and Cardiovascular Medicine

CiteScore

5.70

自引率

5.40%

发文量

审稿时长

5 weeks

期刊介绍： Global Heart offers a forum for dialogue and education on research, developments, trends, solutions and public health programs related to the prevention and control of cardiovascular diseases (CVDs) worldwide, with a special focus on low- and middle-income countries (LMICs). Manuscripts should address not only the extent or epidemiology of the problem, but also describe interventions to effectively control and prevent CVDs and the underlying factors. The emphasis should be on approaches applicable in settings with limited resources. Economic evaluations of successful interventions are particularly welcome. We will also consider negative findings if important. While reports of hospital or clinic-based treatments are not excluded, particularly if they have broad implications for cost-effective disease control or prevention, we give priority to papers addressing community-based activities. We encourage submissions on cardiovascular surveillance and health policies, professional education, ethical issues and technological innovations related to prevention. Global Heart is particularly interested in publishing data from updated national or regional demographic health surveys, World Health Organization or Global Burden of Disease data, large clinical disease databases or registries. Systematic reviews or meta-analyses on globally relevant topics are welcome. We will also consider clinical research that has special relevance to LMICs, e.g. using validated instruments to assess health-related quality-of-life in patients from LMICs, innovative diagnostic-therapeutic applications, real-world effectiveness clinical trials, research methods (innovative methodologic papers, with emphasis on low-cost research methods or novel application of methods in low resource settings), and papers pertaining to cardiovascular health promotion and policy (quantitative evaluation of health programs.